Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Rallybio ( (RLYB) ) has issued an announcement.
On March 1, 2026, Rallybio Corporation signed a Merger Agreement to acquire Candid Therapeutics via a wholly owned subsidiary, but Candid terminated the deal on May 3, 2026 after entering an alternative agreement with UCB S.A. As a result of the termination, Rallybio will receive a $50 million termination fee, has agreed mutual releases of claims with Candid and UCB under a May 1 waiver, and plans to withdraw its related Form S-4 registration statement filed with the SEC in March and amended in April 2026.
The waiver arrangements mean Rallybio has relinquished certain rights tied to the now-terminated transaction while securing compensation for its efforts, which may bolster its balance sheet despite losing the planned acquisition. The withdrawal of the S-4 and the clean mutual release framework simplify Rallybio’s regulatory and legal posture, allowing the company to redirect focus and capital toward other strategic opportunities in the competitive rare-disease therapeutics space.
The most recent analyst rating on (RLYB) stock is a Hold with a $8.00 price target. To see the full list of analyst forecasts on Rallybio stock, see the RLYB Stock Forecast page.
Spark’s Take on RLYB Stock
According to Spark, TipRanks’ AI Analyst, RLYB is a Neutral.
The score is driven by strong technical momentum and a highly positive corporate catalyst (merger plus large financing). These are partially offset by weak underlying financial performance, including ongoing losses and significant cash burn despite low leverage.
To see Spark’s full report on RLYB stock, click here.
More about Rallybio
Rallybio Corporation operates in the biopharmaceutical industry, focusing on the development of therapies for patients with severe and rare diseases. The company advances its pipeline through strategic partnerships, licensing, and potential mergers and acquisitions aimed at expanding its portfolio of innovative drug candidates.
Average Trading Volume: 152,931
Technical Sentiment Signal: Buy
Current Market Cap: $49.78M
For a thorough assessment of RLYB stock, go to TipRanks’ Stock Analysis page.